Cargando…

Safety and Immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I First-in-Human Trial

BACKGROUND: Transmission blocking vaccines targeting the sexual-stages of the malaria parasite could play a major role to achieve elimination and eradication of malaria. The Plasmodium falciparum Pfs25 protein (Pfs25) is the most clinically advanced candidate sexual-stage antigen. IMX313, a compleme...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Graaf, Hans, Payne, Ruth O., Taylor, Iona, Miura, Kazutoyo, Long, Carol A., Elias, Sean C., Zaric, Marija, Minassian, Angela M., Silk, Sarah E., Li, Lee, Poulton, Ian D., Baker, Megan, Draper, Simon J., Gbesemete, Diane, Brendish, Nathan J., Martins, Filipa, Marini, Arianna, Mekhaiel, David, Edwards, Nick J., Roberts, Rachel, Vekemans, Johan, Moyle, Sarah, Faust, Saul N., Berrie, Eleanor, Lawrie, Alison M., Hill, Fergal, Hill, Adrian V. S., Biswas, Sumi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8318801/ https://www.ncbi.nlm.nih.gov/pubmed/34335606 http://dx.doi.org/10.3389/fimmu.2021.694759

Ejemplares similares

Enhancing immunogenicity and transmission-blocking activity of malaria vaccines by fusing Pfs25 to IMX313 multimerization technology
por: Li, Yuanyuan, et al.
Publicado: (2016)

Combination of RTS,S and Pfs25-IMX313 Induces a Functional Antibody Response Against Malaria Infection and Transmission in Mice
por: Brod, Florian, et al.
Publicado: (2018)

Evaluation of the Pfs25-IMX313/Matrix-M malaria transmission-blocking candidate vaccine in endemic settings
por: Mulamba, Charles, et al.
Publicado: (2022)

A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults
por: Minhinnick, Alice, et al.
Publicado: (2016)

Poor CD4(+) T Cell Immunogenicity Limits Humoral Immunity to P. falciparum Transmission-Blocking Candidate Pfs25 in Humans
por: Zaric, Marija, et al.
Publicado: (2021)

Phase Ia Clinical Evaluation of the Safety and Immunogenicity of the Plasmodium falciparum Blood-Stage Antigen AMA1 in ChAd63 and MVA Vaccine Vectors
por: Sheehy, Susanne H., et al.
Publicado: (2012)

Immunogenicity of ChAd63 + MVA ME-TRAP in Senegalese adults
por: Mensah, Victorine, et al.
Publicado: (2014)

Evaluation of the Efficacy of ChAd63-MVA Vectored Vaccines Expressing Circumsporozoite Protein and ME-TRAP Against Controlled Human Malaria Infection in Malaria-Naive Individuals
por: Hodgson, Susanne H., et al.
Publicado: (2015)

A Phase Ia Study to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidates ChAd63 CS Administered Alone and with MVA CS
por: de Barra, Eoghan, et al.
Publicado: (2014)

Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP
por: Rampling, Tommy, et al.
Publicado: (2018)

Structure of the malaria vaccine candidate Pfs48/45 and its recognition by transmission blocking antibodies
por: Ko, Kuang-Ting, et al.
Publicado: (2022)

A novel Plasmodium vivax vaccine based on recombinant chimpanzee adenovirus ChAd63 and MVA expressing TRAP
por: Bauza, Karolis, et al.
Publicado: (2012)

Humoral immunogenicity of ChAd63_MVA ME-TRAP vaccination in African infants and children
por: Bowyer, Georgina, et al.
Publicado: (2014)

Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants
por: Afolabi, Muhammed O, et al.
Publicado: (2016)

Safety and Immunogenicity of Heterologous Prime-Boost Immunisation with Plasmodium falciparum Malaria Candidate Vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in Healthy Gambian and Kenyan Adults
por: Ogwang, Caroline, et al.
Publicado: (2013)

Structural basis for recognition of the malaria vaccine candidate Pfs48/45 by a transmission blocking antibody
por: Lennartz, Frank, et al.
Publicado: (2018)

Particle-based, Pfs230 and Pfs25 immunization is effective, but not improved by duplexing at fixed total antigen dose
por: Huang, Wei-Chiao, et al.
Publicado: (2020)

Assessment of Humoral Immune Responses to Blood-Stage Malaria Antigens following ChAd63-MVA Immunization, Controlled Human Malaria Infection and Natural Exposure
por: Biswas, Sumi, et al.
Publicado: (2014)

Synergistic Effects of IMX-104 Components in Membrane Absorption: A Computational Study
por: Li, Huarong, et al.
Publicado: (2022)

Clinical Assessment of a Recombinant Simian Adenovirus ChAd63: A Potent New Vaccine Vector
por: O’Hara, Geraldine A., et al.
Publicado: (2012)

Protective CD8(+) T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation
por: Ewer, Katie J., et al.
Publicado: (2013)

The Pfs230 N-terminal fragment, Pfs230D1+: expression and characterization of a potential malaria transmission-blocking vaccine candidate
por: Lee, Shwu-Maan, et al.
Publicado: (2019)

Analysis of human B-cell responses following ChAd63-MVA MSP1 and AMA1 immunization and controlled malaria infection
por: Elias, Sean C, et al.
Publicado: (2014)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults
por: Pathan, Ansar A., et al.
Publicado: (2012)

A Universal Plug-and-Display Vaccine Carrier Based on HBsAg VLP to Maximize Effective Antibody Response
por: Marini, Arianna, et al.
Publicado: (2019)

Structure and function of a malaria transmission blocking vaccine targeting Pfs230 and Pfs230-Pfs48/45 proteins
por: Singh, Kavita, et al.
Publicado: (2020)

Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal
por: Mensah, Victorine A., et al.
Publicado: (2016)

Impact of exposure to malaria and nutritional status on responses to the experimental malaria vaccine ChAd63 MVA ME-TRAP in 5-17 month-old children in Burkina Faso
por: Morter, Richard, et al.
Publicado: (2022)

First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children
por: Tiono, Alfred B., et al.
Publicado: (2018)

Identification of domains within Pfs230 that elicit transmission blocking antibody responses
por: Tachibana, Mayumi, et al.
Publicado: (2019)

A human antibody epitope map of the malaria vaccine antigen Pfs25
por: Shukla, Niharika, et al.
Publicado: (2023)

Safety and Immunogenicity of the Heterosubtypic Influenza A Vaccine MVA-NP+M1 Manufactured on the AGE1.CR.pIX Avian Cell Line
por: Folegatti, Pedro M., et al.
Publicado: (2019)

New adenovirus-based vaccine vectors targeting Pfs25 elicit antibodies that inhibit Plasmodium falciparum transmission
por: McGuire, Kathleen A., et al.
Publicado: (2017)

Preclinical development of a Pfs230-Pfs48/45 chimeric malaria transmission-blocking vaccine
por: Singh, Susheel K., et al.
Publicado: (2021)

N-Terminal Pfs230 Domain Produced in Baculovirus as a Biological Active Transmission-Blocking Vaccine Candidate
por: Lee, Shwu-Maan, et al.
Publicado: (2017)

The Role of the st313-td Gene in Virulence of Salmonella Typhimurium ST313
por: Herrero-Fresno, Ana, et al.
Publicado: (2014)

Assessment of Pfs25 expressed from multiple soluble expression platforms for use as transmission-blocking vaccine candidates
por: Lee, Shwu-Maan, et al.
Publicado: (2016)

Structural delineation of potent transmission-blocking epitope I on malaria antigen Pfs48/45
por: Kundu, Prasun, et al.
Publicado: (2018)

Pfs230 yields higher malaria transmission–blocking vaccine activity than Pfs25 in humans but not mice
por: Healy, Sara A., et al.
Publicado: (2021)

Chad : development potential and constraints /
Publicado: (1974)

Cannot write session to /tmp/vufind_sessions/sess_vrk2td6jkbvcha6p8j24uads2u